Table 1. Clinical and laboratory characteristics of the participants.
Variables | Metastasis (n = 58) | Non-metastasis (n = 32) | P-value |
---|---|---|---|
Breast cancer (n) | 9 | 3 | NA |
Lung cancer (n) | 9 | 4 | NA |
Colon cancer (n) | 6 | 2 | NA |
Gastric cancer (n) | 7 | 3 | NA |
Rectal cancer (n) | 5 | 3 | NA |
Lymphoma (n) | 3 | 6 | NA |
Ovarian cancer (n) | 5 | 2 | NA |
Cervical cancer (n) | 3 | 2 | NA |
Esophagus cancer (n) | 3 | 2 | NA |
Nasopharynx cancer (n) | 3 | 2 | NA |
Other cancers (n) | 5 | 3 | NA |
Ages (years) | 51.5 (12.2) | 47.4 (15.5) | 0.102 |
Gender (males,%) | 25 (43.9) | 12 (44.4) | 0.056 |
DcR3 (pg/ml)* | 335.6 (413.6) | 228.5 (173.7) | <0.05 |
PDW (%) | 14.1 (13.9) | 11.8 (1.9) | 0.058 |
Haemoglobin (g/dl)* | 112.2 (24.1) | 124.5 (16.7) | <0.05 |
Hematocrit (%)* | 34.6 (6.8) | 38.1 (5.1) | <0.05 |
DcR3 × PDW ÷ (HGB × HCT)*** | 1.4 (1.9) | 0.4 (0.2) | <0.001 |
Data are presented as means(SD). P-Value was calculated by chi-square test (Age) or Mann-Whitney U test. Metastasis includes lymph node metastasis and distant metastasis. The number of patients tested (n) is shown.
*compared with non-metastatic cancers, P < 0.05.
***compared with non-metastatic cancers, P < 0.001.